Key clinical point: High-risk multigene testing for all patients with breast cancer may be a cost-effective way to reduce cases of breast cancer and ovarian cancer, with related reductions in mortality.
Major finding: In the United States, multigene testing for all patients with breast cancer could prevent 9,733 cases of breast cancer and ovarian cancer and 2,406 cancer-related deaths per year.
Study details: A microsimulation modeling study involving 11,836 patients with breast cancer.
Disclosures: The study was funded by the National Cancer Institute, the State of Washington, the Fred Hutchinson Cancer Research Center, and others. The investigators reported additional relationships with AstraZeneca, the Manchester National Institute for Health Research Biomedical Research Centre, Cancer Research UK, an others.
Sun et al. JAMA Oncol. 2019 Oct 3. doi: 10.1001/jamaoncol.2019.3323.